Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purified omental lipid (P.O.L.) is a topical lipid extract derived from porcine omentum, a peritoneal tissue rich in neutral glycerides, phospholipids, glycolipids, and gangliosides. Developed by Cantabria Labs Difa Cooper, it is commercialized as a topical emollient and skin-protective medical device (such as P.O.L. cream) to restore skin barrier function, promote hydration, and support wound healing. It is used for the management of fragile skin, skin dryness (xerosis) in diabetic patients, and the prevention of pressure ulcers. Additionally, formulations combining purified omental lipids with anti-pruritic agents (such as polidocanol and palmitoylethanolamide) have been clinically evaluated and marketed for the treatment of chronic pruritus and prurigo nodularis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on purified omental lipid.